Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: ...
1.0 Credit / Hematologic Cancer
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and...
1.0 Credit / Hematologic Cancer
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Pract...
1.0 Credit / Hematologic Cancer, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operati...
1.0 Credit / Hematologic Cancer, Oncology
View More
Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
1.0 Credit / Breast Cancer, Women’s Health, Oncology
View More
HOPA 2025: Advancements and Challenges in Neoadjuvant Therapy for Regional Melanoma
April 11th 2025Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.
HOPA 2025: The Promise and Pitfalls of ctDNA Testing in Oncology
April 11th 2025Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.
Financial Incentives for COVID-19 Vaccination May Have Adverse Spillover Effects on Booster Uptake
April 9th 2025Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have invertedly turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.
SGO 2025: The MRI Gap and How Race and Insurance Shape Cervical Cancer Treatment Timelines
April 8th 2025Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.